Eupraxia Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-3.7%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$0.95next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Short-Term Investments Quarterly138.9MTarget: Sufficient to fund operations into H2 2028
RESOLVE Phase 2b Trial Enrollment QuarterlyTarget: At least 120 patients
Quarterly Net Loss Quarterly12.7MTarget: Minimize operational cash burn
Watch Items
- RESOLVE Phase 2b Top-line Data ReadoutTrigger: Q4 2026Action: Evaluate efficacy and safety of 120mg and 160mg doses of EP-104GI in Eosinophilic Esophagitis
- North American Tariff EnvironmentTrigger: Implementation of proposed 25% tariffs on Canadian imports or retaliatory tariffsAction: Assess impact on the cost of U.S.-manufactured clinical supplies and active pharmaceutical ingredients
- PROMENADE 1 & 2 Phase 3 Trials for EP-104IARTrigger: Clinical milestones and patient follow-up timelinesAction: Monitor safety and durability of single and repeat doses in knee osteoarthritis patients
Research as of 20 Jun 2026